Novel oncology modalities such as antibody-drug conjugates (ADCs), as well as bispecific and multi-specific antibodies, show significant promise for cancer treatment and accounted for a notable 35% of oncology trials in 2024.
Spending on this new class of targeted therapies is expected to increase ten-fold between now and 2029, driven by new launches, expansion to new indications, and use in earlier lines of therapy. In a challenging and increasingly competitive landscape, how can innovative and integrated RWE approaches help accelerate clinical development, maximize patient access, inform treatment decision-making, and establish real-world efficacy and safety?
IQVIA is using vast quantities of data in powerful new ways. See how we can help you tap into information from past trials, patient reported outcomes and other sources to accelerate your research.
.svg){kind=icon}
